This trial is active, not recruiting.

Condition liver transplant recipients
Sponsor Baylor Research Institute
Start date October 2002
End date November 2014
Trial size 200 participants
Trial identifier NCT01525797, 002-197


The purpose of this study is to see what a lab test will show and if there is a way to predict which patients will be more likely to have rejection after receiving a liver transplant.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective

Primary Outcomes

Identify signatures predictive of graft rejection or tolerance.
time frame: 2 years

Eligibility Criteria

Male or female participants from 17 years up to 65 years old.

Inclusion Criteria: - Received a liver Transplant Exclusion Criteria: - Received Multiple Organ Transplant

Additional Information

Official title Immunomonitoring of Transplant Patients
Principal investigator Goran Klintmalm, MD
Description The purpose of this study is simply to see what the new oligonucleotide microarrays will show when comparing the the different patient groups. The results of this study will be one of the first steps In exploring the potential use of this new test.
Trial information was received from ClinicalTrials.gov and was last updated in March 2014.
Information provided to ClinicalTrials.gov by Baylor Research Institute.